2Cadianan Erythropoietin Study Group. Association between recombinant human erythropoi - etin and quality of life and exercise capacity patients receiving hemodialysis. Brit Med J, 1990, 300 : 5738.
3Adamson JW,Eschbach JW. Treatment of the anemia of chronic renal failure with recombinant human erythropoietin. Annu Rev Med, 1990,41:349.
4Francesco Locatelli MD,Conrad A,Baldamus MD,et al. Onceweekly compares with three - times weekly subcutaneous epoetin β:results from a randomized, multicenter, therapeutic- equivalence study Am J of Kid. Disease, 2002,40 (1) : 20 - 40.
6Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in he- modialysis patients[ J]. Am J Kidney Dis ,2002,40 : 439-446.
7KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease[J]. Kidney Int Suppl ,2012 , 2(4) :$299-310.
8Ma JZ,Ebben J,Xia H,et al. Hematoerit Level and associated mortali- ty in hemodialysis patients [ J ]. Am Soc Nephrol, 1999, 10 (3) :610- 619.
9Delano BG. hnprovements in quality of life following treatment with rhEPO in anemic hemodialysis patients [ J ]. Am J Kidney D/s, 1989, 14(2):14-18.
10Vanrenterghem Y, Barany P,Johannes FE,et al. Randomized trial of darbe-poetin alfa for treatment of renal anemia at a reduced does fue- quency compared with rHuEPO in dialysis patients [ J ]. Kid lnt, 2002,62(21 ) :2167-2175.
